Noxopharm says the FDA has supported its proposed Phase II design and chemical manufacturing strategy for SOF-SKN, its topical treatment candidate for cutaneous lupus erythematosus. The feedback improves regulatory clarity, but the trial remains targeted for the first half of calendar 2028 and is subject to further studies and regulatory requirements.
- Supportive FDA pre-IND feedback on Phase II design
- Chemical manufacturing strategy received particular backing
- Future US IND submission remains in preparation
- Phase II trial targeted for H1 calendar 2028
- Potential Orphan Drug Designation opportunity remains ungranted
FDA supports proposed SOF-SKN development route
Noxopharm Limited (ASX:NOX) has cleared an important regulatory discussion for SOF-SKN, with the US Food and Drug Administration supporting the company’s proposed Phase II clinical trial approach for its autoimmune disease candidate.
The FDA’s pre-Investigational New Drug feedback also backed Noxopharm’s chemical manufacturing strategy and provided technical guidance on non-clinical safety studies. The company said the agency considered the proposed Phase II design reasonable, giving it a clearer framework for the technical work required before a future US IND submission.
Pre-IND meeting reduces uncertainty, not development risk
The meeting follows Noxopharm’s formal request in July for FDA feedback on SOF-SKN’s clinical development pathway, after the company had already begun preparations for the US regulatory process. Those preparations included the pre-IND meeting request, which was intended to clarify clinical and manufacturing plans for the candidate.
Noxopharm said it will incorporate the FDA’s comments into a series of substantive technical studies leading towards the trial. That gives the company a more defined route, but the announcement does not represent an IND clearance, Phase II approval or evidence that SOF-SKN is clinically effective.
Phase II target set for first half of 2028
The company is targeting the Phase II trial for the first half of calendar 2028, subject to regulatory feedback as well as standard clinical and manufacturing requirements. It is also preparing for a future IND submission that could support US clinical development and, according to Noxopharm, potentially improve SOF-SKN’s commercial attractiveness to industry.
The timing leaves a substantial period for further work. Noxopharm’s earlier engagement of Novotech for the US regulatory strategy formed part of the lead-up to this process, while manufacturing of SOF-SKN had also been reported as underway ahead of clinical development.
Cutaneous lupus study remains the next clinical step
Noxopharm is in final preparations for an extension study in patients with cutaneous lupus erythematosus, or CLE, in Melbourne. CLE is a skin manifestation of lupus, and the company says no therapies are currently specifically approved for the condition.
Noxopharm also identified a potential Orphan Drug Designation opportunity for SOF-SKN, citing the lack of targeted therapies for CLE. That designation has not been granted, however, and the company’s reference to a global market valued at US$5.4 billion in 2024 does not establish a forecast revenue opportunity for SOF-SKN.
Sofra platform may gain regulatory learnings
The company said the FDA engagement could also inform regulatory planning for other assets built on its Sofra technology platform, which uses synthetic nucleic acids to modulate innate immune signalling. That broader benefit remains prospective: the immediate regulatory feedback relates to SOF-SKN and its proposed development plan.
For now, the key test is execution between a supportive consultation and a clinical trial still more than a year away. Completion of the technical and non-clinical studies, manufacturing readiness and progress towards the IND submission will determine whether the clearer pathway translates into a trial on the stated timetable.
Bottom Line?
The FDA has reduced regulatory ambiguity around SOF-SKN, but Noxopharm still has to complete the technical, manufacturing and clinical work needed to reach its 2028 Phase II target.
Questions in the middle?
- What additional non-clinical studies will the FDA feedback require before an IND submission?
- Can Noxopharm maintain the H1 calendar 2028 trial target as manufacturing and regulatory work progresses?
- Will the company pursue and secure Orphan Drug Designation for SOF-SKN in cutaneous lupus erythematosus?